TAUOPATHIES, PICKS, AND PRIONS
NEURODEGENERATIVE DISEASES AND PRIONS
List of authors.
Stanley B. Prusiner, M.D.
May 17, 2001
N Engl J Med 2001; 344:1516-1526
DOI: 10.1056/NEJM200105173442006
Article Figures/Media 119 References 584 Citing Articles Related Articles
Twenty-five years ago, little was known about the causes of neurodegenerative diseases. Now, however, it is clear that they result from abnormalities in the processing of proteins. In each of these diseases, defective processing causes the accumulation of one or more specific neuronal proteins. Of all the laboratory research on neurodegenerative diseases, the studies that led to the discovery of prions have yielded the most unexpected findings. The idea that a protein can act as an infectious pathogen and cause degeneration of the central nervous system was accepted only after a long and arduous battle.1 The concept of prions not only has provided an explanation of how a disease can be both infectious and genetic, but has also revealed hitherto unknown kinds of neurologic diseases. This review presents a unifying concept of degenerative brain diseases, based on what we have learned about prions.2
Table 1.
nejm200105173442006_t1.jpeg
Prevalence of Neurodegenerative Diseases in the United States in 2000.
Alzheimer's disease is the most common neurodegenerative disorder (Table 1). In the United States, approximately 4 million people have Alzheimer's disease, and approximately 1 million have Parkinson's disease.3-5Much less common are amyotrophic lateral sclerosis, frontotemporal dementia, prion diseases, Huntington's disease, and spinocerebellar ataxias.
With the increase in life expectancy, there has been concern about the incidence of Alzheimer's and Parkinson's diseases. Among persons who are 60 years old, the prevalence of Alzheimer's disease is approximately 1 in 10,000, but among those who are 85 years old, it is greater than 1 in 3.6 These data suggest that by 2025, there will be more than 10 million cases of Alzheimer's disease in the United States, and by 2050, the number will approach 20 million.4 The annual cost associated with Alzheimer's disease in the United States is estimated at $200 billion. Age is also the most important risk factor for Parkinson's disease. Nearly 50 percent of persons who are 85 years old also have at least one symptom or sign of parkinsonism.7
Virtually all neurodegenerative disorders involve abnormal processing of neuronal proteins. The aberrant mechanism can entail a misfolding of proteins, altered post-translational modification of newly synthesized proteins, abnormal proteolytic cleavage, anomalous gene splicing, improper expression, or diminished clearance of degraded protein. Misprocessed proteins often accumulate because the cellular mechanisms for removing them are ineffective. The particular protein that is improperly processed determines the malfunction of distinct sets of neurons and thus the clinical manifestations of the disease.
Prions
Prions are infectious proteins. In mammals, prions reproduce by recruiting normal cellular prion protein (PrPC) and stimulating its conversion to the disease-causing (scrapie) isoform (PrPSc). A major feature that distinguishes prions from viruses is that PrPSc is encoded by a chromosomal gene.8 Limited proteolysis of PrPSc produces a smaller, protease-resistant molecule of approximately 142 amino acids, designated PrP 27–30, which polymerizes into amyloid.9
Figure 1.
nejm200105173442006_f1.jpeg
Structures of Prion Protein (PrP) Isoforms.
The polypeptide chains of PrPC and PrPSc are identical in composition but differ in their three-dimensional, folded structures (conformations). PrPC is rich in α-helixes (spiral-like formations of amino acids) and has little β-sheet (flattened strands of amino acids), whereas PrPSc is less rich in α-helixes and has much more β-sheet.10 There is evidence that PrPC has three α-helixes and two short β-strands; in contrast, a plausible model suggests that PrPScmay have only two α-helixes and more β-strands (Figure 1).11,12 This structural transition from α-helixes to β-sheet in PrP is the fundamental event underlying prion diseases.
Four new concepts have emerged from studies of prions. First, prions are the only known example of infectious pathogens that are devoid of nucleic acid. All other infectious agents possess genomes composed of either RNA or DNA that direct the synthesis of their progeny. Second, prion diseases may be manifested as infectious, genetic, or sporadic disorders. No other group of illnesses with a single cause has such a wide spectrum of clinical manifestations. Third, prion diseases result from the accumulation of PrPSc, which has a substantially different conformation from that of its precursor, PrPC. Fourth, PrPSc can have a variety of conformations, each of which seems to be associated with a specific disease. How a particular conformation of PrPSc is imparted to PrPC during replication in order to produce a nascent PrPSc with the same conformation is unknown. The factors that determine the site in the central nervous system where a particular PrPSc is deposited are also not known.
Prion Diseases
Prion diseases have a broad spectrum of clinical manifestations, including dementia, ataxia, insomnia, paraplegia, paresthesias, and deviant behavior.13 Neuropathological findings range from an absence of atrophy to widespread atrophy, from minimal to widespread neuronal loss, from sparse to widespread vacuolation or spongiform changes, from mild to severe reactive astrocytic gliosis, and from an absence of PrP amyloid plaques to an abundance of plaques.14None of these findings except the presence of PrP amyloid plaques is unequivocally diagnostic of a prion disease.
Table 2.
nejm200105173442006_t2.jpeg
Pathogenetic Features of Prion Diseases.
The sporadic form of Creutzfeldt–Jakob disease, which is typically manifested as dementia and myoclonus, accounts for approximately 85 percent of all cases of prion disease in humans, whereas infectious and inherited prion diseases account for the rest. Familial Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker disease, and fatal familial insomnia are all dominantly inherited prion diseases caused by mutations in the prion protein gene (PRNP) (Table 2).15-19 Experiments that showed transmission of these diseases by filtrates of brain from familial cases20,21 were wrongly attributed to a virus. There is no Creutzfeldt–Jakob disease virus, and familial prion diseases are caused by mutations in PRNP. 22
EPIDEMIOLOGIC FEATURES
Prions cause Creutzfeldt–Jakob disease in humans throughout the world. The incidence of sporadic Creutzfeldt–Jakob disease is approximately 1 case per 1 million population,23 but among persons between the ages of 60 and 74 years, the incidence is nearly 5 per 1 million.24 Cases in patients as young as 17 years and as old as 83 have been recorded.23,25 Creutzfeldt–Jakob disease is relentlessly progressive and usually causes death within a year after its onset. Each geographic cluster of cases of prion disease was initially thought to be a manifestation of viral communicability,26 but each was later shown to be due to a PRNP gene mutation except for new variant Creutzfeldt–Jakob disease.
NEUROPATHOLOGICAL FEATURES
Figure 2.
nejm200105173442006_f2.jpeg
Neuropathological Features of Prion Diseases in Humans.
There are often no recognizable gross abnormalities in the brains of patients with Creutzfeldt–Jakob disease. Patients who survive for several years have variable degrees of cerebral atrophy. The microscopical features of Creutzfeldt–Jakob disease are spongiform degeneration and astrogliosis (Figure 2A and Figure 2B).27
Amyloid plaques occur in approximately 10 percent of cases of Creutzfeldt–Jakob disease. These plaques are positive for antibodies against PrPSc on immunohistochemical staining.28,29 The amyloid plaques in patients with Gerstmann–Sträussler–Scheinker disease consist of a dense core of amyloid surrounded by smaller globules of amyloid (Figure 2). A characteristic feature of new variant Creutzfeldt–Jakob disease is the presence of “florid plaques” composed of a core of PrPSc amyloid surrounded by vacuoles (Figure 2E and Figure 2F).
STRAINS OF PRIONS
The existence of prion strains raises the question of how heritable biologic information can be encrypted in a molecule other than nucleic acid.30-32 Strains of prions have been defined by the rapidity with which they cause central nervous system disease and by the distribution of neuronal vacuolation.30 Patterns of PrPSc deposition have also been used to characterize these strains.33,34There is mounting evidence that the diversity of prions is enciphered in the conformation of the PrPSc protein.35-39 Studies involving the transmission of fatal familial insomnia and familial Creutzfeldt–Jakob disease to mice expressing a chimeric human–mouse PrP transgene have shown that the tertiary and quaternary structure of PrPSc contains strain-specific information.37Studies of patients with fatal sporadic insomnia have extended these findings,40 making it clear that PrPSc acts as a template for the conversion of PrPC into nascent PrPSc.
SPORADIC, GENETIC, AND INFECTIOUS FORMS OF PRION DISEASE
Sporadic prion diseases might be initiated by a somatic mutation and in this respect might develop in a manner similar to prion diseases caused by germ-line mutations. In this situation, the mutant PrPSc must be capable of recruiting wild-type PrPC, a process that may occur with some mutations but is unlikely with others.41 Alternatively, the activation barrier separating wild-type PrPC from PrPSc may be crossed on rare occasions in the context of a large population of people.42 Twenty mutations in the human PRNP gene have been found to segregate with inherited prion diseases.43 Missense mutations and expansions in the octapeptide-repeat region of the gene cause familial prion diseases.15-19
Although infectious prion diseases constitute less than 1 percent of all cases of prion disease, the circumstances surrounding the transmission of these infectious illnesses are often dramatic (Table 2). Ritualistic cannibalism has resulted in the transmission of kuru among the Fore people of New Guinea, industrial cannibalism has been responsible for bovine spongiform encephalopathy (BSE), or “mad cow disease,” in Europe, and an increasing number of patients have contracted new variant Creutzfeldt–Jakob disease from prion-tainted beef products.13
The restricted geographic and temporal distribution of cases of new variant Creutzfeldt–Jakob disease raises the possibility that BSE prions have been transmitted to humans. Although over 100 cases of new variant Creutzfeldt–Jakob disease have been recorded,44,45 no dietary habits distinguish patients with this disease from apparently healthy persons. Moreover, it is unclear why teenagers and young adults seem to be particularly susceptible to the disease. These cases may mark the start of an epidemic of prion disease in Great Britain like those of BSE and kuru, or the number of cases of new variant Creutzfeldt–Jakob disease may remain small, as with iatrogenic Creutzfeldt–Jakob disease caused by cadaveric human growth hormone.46
The most compelling evidence that new variant Creutzfeldt–Jakob disease is caused by BSE prions comes from studies of mice expressing the bovine PrP transgene.47 The incubation times, neuropathological features, and patterns of PrPSc deposition in these transgenic mice are the same whether the inoculate originated from the brains of cattle with BSE or from humans with new variant Creutzfeldt–Jakob disease.47 The origin of BSE is still obscure, although epidemiologic studies indicate that BSE probably arose from a single point source in the southwest of England in the 1970s.48 It probably originated from a rare case of prion disease in either sheep (Scott M, Prusiner SB: unpublished data) or cattle.48 Once established, the disease was spread in cattle by ingestion of prion-contaminated meat and bone meal.
The accidental transmission of Creutzfeldt–Jakob disease to humans appears to have occurred with corneal transplantation49 and use of contaminated electroencephalographic electrodes.50The same improperly decontaminated electrodes that had caused Creutzfeldt–Jakob disease in two young patients with intractable epilepsy were found to cause Creutzfeldt–Jakob disease in a chimpanzee 18 months after their implantation in the animal.51 More than 70 cases of Creutzfeldt–Jakob disease associated with the implantation of dura mater grafts have been recorded.52 One case occurred after the repair of a perforated eardrum with a pericardial graft.53Prion-contaminated human growth hormone preparations derived from human pituitary tissue have caused fatal cerebellar disorders with dementia in more than 120 patients ranging in age from 10 to 41 years.13,54,55 Four cases of Creutzfeldt–Jakob disease have occurred in women who received human pituitary gonadotropin.56 Polymorphisms influence the susceptibility to sporadic, inherited, and infectious forms of prion disease. Dominant negative alleles in approximately 12 percent of the Japanese population57encode for lysine at position 219 and interfere with the conversion of wild-type PrPC into PrPSc.58,59 Dominant negative inhibition of prion replication has also been found in sheep, with a substitution of the basic residue arginine at position 171.60,61
Other Neurodegenerative Diseases
Like cases of the prion diseases, most cases of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia are sporadic; 10 percent or less are inherited. Although age is the most important risk factor in all these sporadic forms of disease, the factors that initiate neurodegeneration remain unknown. In the prion diseases, the initial formation of PrPSc leads to an exponential increase in the protein, which can be readily transmitted to another host. In the other neurodegenerative diseases, the events that lead to the production of aberrantly processed proteins, as well as the driving forces that sustain their accumulation, are unknown. It is important to stress that in contrast to the prion diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia are not infectious and have not been transmitted to laboratory animals.
ALZHEIMER'S DISEASE
Table 3.
nejm200105173442006_t3.jpeg
Protein Deposition in Neurodegenerative Diseases.
Table 4.
nejm200105173442006_t4.jpeg
Mutant Genes in Familial Neurodegenerative Diseases.
Aβ-amyloid plaques and neurofibrillary tangles are found in both sporadic and inherited forms of Alzheimer's disease (Table 3). Like familial prion diseases, familial Alzheimer's disease has an autosomal dominant pattern of inheritance. Familial Alzheimer's disease can be caused by a mutation in the gene for amyloid precursor protein (APP), presenilin 1, or presenilin 2 (Table 4).62 Cleavage of amyloid precursor protein at residue 671 by β-secretase and at either residue 711 or residue 713 by γ-secretase produces Aβ(1–40) and Aβ(1–42), respectively. Aβ(1–42) forms amyloid fibrils readily and is thought to cause central nervous system dysfunction before it is deposited in plaques.63-65 Presenilin 1 and presenilin 2 may form complexes with at least one other protein, nicastrin, a transmembrane neuronal glycoprotein, and these complexes may contribute to the production of Aβ(1–42).66
The age of onset of both sporadic and familial forms of Alzheimer's disease is modulated by allelic variants of apolipoprotein E.67 Three alternative allelic products of apolipoprotein E, denoted ε2, ε3, and ε4, differ at amino acid residues 112 and 158. In many persons with two ε4 alleles, Alzheimer's disease develops at least a decade before it does in those with two copies of ε2, and ε3 is associated with an onset of disease at an intermediate age.68
FRONTOTEMPORAL DEMENTIA AND PICK'S DISEASE
Mutations in the tau gene, which codes for tau, a protein associated with microtubules, cause inherited forms of frontotemporal dementia and Pick's disease.69-71 As with Alzheimer's disease, about 90 percent of cases of frontotemporal dementia are sporadic, and the rest are familial. Straight filaments composed of hyperphosphorylated mutant tau have been found in the brains of patients with familial frontotemporal dementia (Table 3).72 In some cases, neurofibrillary tangles composed of paired helical filaments have been found; the formation of these filaments seems to depend on the specific mutation and on the specific isoform of the protein (Table 4).73In sporadic cases of frontotemporal dementia, aggregates of tau are uncommon. Approximately 15 percent of patients with frontotemporal dementia have Pick bodies,74 which are intracellular collections of partially degraded (ubiquinated) tau fibrils in the brain.75 As with frontotemporal dementia, most cases of Pick's disease are sporadic. Other disorders caused by the misprocessing of tau include progressive supranuclear palsy, progressive subcortical gliosis, and corticobasal degeneration.73,75-77
PARKINSON'S DISEASE
Most cases of Parkinson's disease are sporadic,78,79 but both sporadic and familial forms of the disease are characterized by protein deposits in the central nervous system. Mutations in the gene for α-synuclein have been found in patients with familial Parkinson's disease.80 In both sporadic and familial cases, antibodies to α-synuclein, a presynaptic intracellular protein, stain Lewy bodies in neurons of the substantia nigra.81 Whereas the inheritance of Parkinson's disease due to mutations in the α-synuclein gene is autosomal dominant, a childhood form of the disease due to mutations in the gene for ubiquitin–protein ligase (parkin) is a recessive disorder (Table 4).82 Parkin seems to promote the degradation of certain neuronal proteins, and selective nitration of α-synuclein has been observed in Lewy bodies.83
Parkinson's disease in older persons is associated with a high incidence of dementia.84 At autopsy, the brains of such patients often have the neuropathological hallmarks of both Alzheimer's disease and Parkinson's disease. Immunohistochemical studies showing the presence of α-synuclein in cortical Lewy bodies have helped resolve the conundrum of how a patient could have insufficient numbers of plaques and neurofibrillary tangles for the diagnosis of Alzheimer's disease but still have dementia. The presence of these α-synuclein deposits, alone or in combination with changes that are characteristic of Alzheimer's disease, may be the second most common form of neurodegeneration, accounting for 20 to 30 percent of cases of dementia among persons over the age of 60 years.85,86 A small number of younger persons with Parkinson's disease also have dementia due to diffuse Lewy body disease.87
AMYOTROPHIC LATERAL SCLEROSIS
Although most cases of amyotrophic lateral sclerosis are sporadic, familial cases have been identified.88-90 In approximately 20 percent of familial cases of amyotrophic lateral sclerosis, there are mutations in the gene for cytoplasmic superoxide dismutase type 1 (SOD1) (Table 4).91Moreover, deposits of SOD1 in the central nervous system have been found in both sporadic and familial cases of amyotrophic lateral sclerosis.92 Although in some cases abnormal collections of neurofilaments have been seen in degenerating motor neurons, no familial cases have been shown to be due to mutations in neurofilament genes.92
HUNTINGTON'S DISEASE AND SPINOCEREBELLAR ATAXIAS
Unlike Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, and the prion diseases, which in most cases are sporadic, all cases of Huntington's disease and of spinocerebellar ataxia are caused by expanded polyglutamine repeats (Table 4).93-95 But these diseases are similar to the inherited forms of Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, and the prion diseases in that they are usually manifested as neurologic deficits in adulthood, even though the expression of the mutant gene products in the central nervous system begins early in life. Childhood forms of Huntington's disease and spinocerebellar ataxia are known to be due to large expansions of the causative triplet repeats.94,96,97
TRANSGENIC MOUSE MODELS
Although virtually every facet of the human and animal prion diseases has been reproduced in transgenic mice, attempts to develop transgenic models for the other neurodegenerative diseases have proved more difficult. Despite the lack of perfect transgenic models for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementias, Huntington's disease, and the spinocerebellar ataxias, many aspects of these human disorders have been reproduced. Mice expressing transgenes carrying mutations found in the inherited forms of these neurodegenerative diseases develop disorders with many of the neuropathological features that characterize the corresponding human illnesses (Table 3 and Table 4).
Diagnostic Tests
There is an urgent need for a rapid, antemortem test for prions in humans and livestock. A highly sensitive quantitative immunoassay has been developed on the basis of antigens that are exposed in PrPC but buried in PrPSc. Unlike earlier immunoassays for PrPSc, this conformation-dependent immunoassay does not require limited proteolysis to hydrolyze PrPC before the protease-resistant core of PrPSc (PrP 27–30) is measured.38 This assay has been used to identify a new form of PrPSc, which is protease-sensitive (sPrPSc).
A diagnostic test would be valuable for distinguishing between early Alzheimer's disease and depression in older persons, since both disorders are so common. In Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and the prion diseases, computed tomography or magnetic resonance imaging may show normal findings or cortical atrophy. In patients with Alzheimer's disease, widespread atrophy with enlarged ventricles is often seen, especially late in the disease, but this finding is not diagnostic. Many elderly persons with normal cognition have similar radiographic findings.98,99 Although many patients with Creutzfeldt–Jakob disease have elevated levels of protein 14-3-3 in cerebrospinal fluid, this finding is not specific for the diagnosis.100,101 Attempts to measure Aβ(1–40) in blood and urine as diagnostic tests have been unrewarding,102 but the use of fluorescence correlation spectroscopy to measure Aβ(1–40) in cerebrospinal fluid may provide a reliable diagnostic test for Alzheimer's disease.103
Whereas electroencephalographic studies are not useful for the diagnosis of Alzheimer's disease, frontotemporal dementia, or Parkinson's disease, they are often useful for the diagnosis of Creutzfeldt–Jakob disease. Repetitive, high-voltage, triphasic and polyphasic sharp discharges are seen in most advanced cases of Creutzfeldt–Jakob disease, but their presence is often transient.25,101,104,105 As the disease progresses, normal background rhythms become fragmentary and slower.
Hashimoto's thyroiditis should always be considered in the differential diagnosis of Creutzfeldt–Jakob disease,106 since the former disorder is a treatable autoimmune disease whereas Creutzfeldt–Jakob disease is not. The clinical and neuropathological findings in these two disorders can be quite similar, raising the possibility that protein misprocessing underlies both degenerative and autoimmune diseases.
Prevention and Treatment
With the exception of levodopa, which ameliorates the symptoms of Parkinson's disease but does not halt the underlying degeneration, there are no effective therapies for neurodegenerative diseases. The history of successful attempts to prevent or reverse protein misprocessing is extremely limited.107 Developing new drugs directed to specific regions of the central nervous system will be challenging.
PREVENTING ABNORMAL PROCESSING OF PROTEINS AND ENHANCING THEIR CLEARANCE
Structure-based drug design based on dominant negative inhibition of prion formation has resulted in the development of several compounds.108 However, the task of exchanging polypeptide scaffolds for small heterocyclic structures without the loss of biologic activity remains difficult. Whether this approach to preventing the aberrant processing of proteins will lead to the development of new treatments for Alzheimer's and Parkinson's diseases, as well as other neurodegenerative disorders, remains to be established.
Several compounds can eliminate prions from cultured cells. A class of compounds known as “dendrimers” seems particularly effective in this regard.109 Some drugs delay the onset of disease in animals that have been inoculated with prions if the drugs are given around the time of the inoculation.110 A novel approach to treating Alzheimer's disease has been developed in transgenic mice that overexpress a mutant APP gene. Immunization of these mice with the Aβ peptide or injection of antibodies to Aβ reduces plaque formation.111 Whether this approach will prove fruitful in patients is unknown.
REPLACEMENT THERAPY
Because the neurodegeneration in Parkinson's disease is confined largely to the substantia nigra, especially early in the disease process, replacement therapy with levodopa has proved useful; in many patients, however, the disease eventually becomes refractory to levodopa.112 Similar approaches to the treatment of Alzheimer's disease have been disappointing, primarily because the disease process is so widespread. Similarly, the widespread neuropathological changes in amyotrophic lateral sclerosis, frontotemporal dementia, and prion diseases make it unlikely that replacement therapy will be successful.
Speculation on the Spectrum of Degenerative Diseases
It is tempting to speculate that abnormal processing of neuronal proteins also occurs in other diseases of the central nervous system, such as schizophrenia, bipolar disorders, autism, and narcolepsy.113 Most cases of these diseases are sporadic, but a substantial minority appear to be familial. The absence of neuropathological changes in these conditions has impeded phenotypic analysis. In a group of patients with inherited frontotemporal dementia who have a mutation in the tau gene, alcoholism and Parkinson's disease are prominent features.114
Whether multiple sclerosis is also the result of defective processing of brain proteins is unknown.115 The immune system features prominently in the pathogenesis of multiple sclerosis, and it is often argued that this disease is a T-cell–mediated, autoimmune disorder. Antibody-mediated demyelination has been found in some cases of multiple sclerosis,116 and in others, degeneration of oligodendrocytes has been observed, with little or no evidence of immune-mediated damage.117 Perhaps ulcerative colitis, Crohn's disease, rheumatoid arthritis, type 1 diabetes mellitus, and systemic lupus erythematosus ought to be considered disorders of protein processing in which misfolded proteins evoke an autoimmune response.
The systemic amyloidoses share important features with the neurodegenerative diseases. In primary amyloidosis, immunoglobulin light chains form amyloid deposits that can cause cardiomyopathy, renal failure, and polyneuropathy.118 In response to chronic inflammatory diseases, the serum amyloid A protein is cleaved and forms the amyloid A protein, which is deposited as fibrils in the kidney, liver, and spleen. The most common form of systemic hereditary amyloidosis is caused by the deposition of mutant transthyretin. Also noteworthy are amylin deposits in the β-islet cells of patients with type 2 diabetes mellitus. These deposits contain amyloid fibrils that are composed of the amylin protein.
The Future
As life expectancy continues to increase, the burden of degenerative diseases is growing. Developing effective means of preventing these disorders and of treating them when they do occur is a paramount challenge. The problems caused by Alzheimer's disease and Parkinson's disease are already so great that if the prevalence of these maladies continues to increase in accordance with the changing demographic characteristics of the world population, they will bankrupt both developed and developing countries over the next 50 years. It is remarkable to think that by the year 2025, more than 65 percent of persons over the age of 65 years will be living in countries that are now designated as developing countries.119 Unless effective methods of prevention and treatment are developed, this enormous population of people will be subjected to the same risks of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders as are older persons currently living in the most affluent countries.
Over the past two decades, remarkable progress has been made in elucidating the causes of neurodegenerative diseases, and the time has come to intensify the search for drug targets and for compounds that interrupt the disease processes. Drugs that block the mishandling of a particular protein may be most effective for certain disorders; for others, drugs that enhance the clearance of an aberrant protein or fragment may prove most useful. Regardless of the therapeutic approach, accurate, early detection of neurodegeneration will be extremely important so that drugs can be given before substantial damage to the central nervous system has occurred. However, the enormity of these tasks — developing useful diagnostic tests and discovering effective therapies — should not be underestimated.
Presented as the 110th Shattuck Lecture to the Annual Meeting of the Massachusetts Medical Society, Boston, May 20, 2000.
Supported by grants from the National Institutes of Health (NS14069, AG02132, and AG10770), the American Health Assistance Foundation, and the Leila and Harold Mathers Foundation.
I am indebted to Drs. Fred Cohen, Stephen DeArmond, Kirk Wilhemsen, Robert Edwards, Warren Olanow, Steve Finkbiener, and Steve Hauser for their valuable comments and suggestions; to Dr. Fred Cohen for preparation of the PrP structural illustrations; and to Dr. Stephen DeArmond for preparation of the photomicrographs.
Author Affiliations
From the Institute for Neurodegenerative Diseases and the Departments of Neurology and of Biochemistry and Biophysics, University of California, San Francisco.
Address reprint requests to Dr. Prusiner at the Institute for Neurodegenerative Diseases, Box 0518, University of California, San Francisco, CA 94143-0518.
Stanley PRUSINER
Stanley Prusiner Portrait.
Senior author Stanley B. Prusiner, MD, director of the UCSF Institute for Neurodegenerative Diseases and professor in the departments of Neurology and of Biochemistry and Biophysics. Image courtesy UCSF Institute for Neurodegenerative Diseases.
“I believe this shows beyond a shadow of a doubt that amyloid beta and tau are both prions, and that Alzheimer’s disease is a double-prion disorder in which these two rogue proteins together destroy the brain,”
said Stanley Prusiner, MD, the study’s senior author and director of the UCSF Institute for Neurodegenerative Diseases, part of the UCSF Weill Institute for Neurosciences.
“The fact that prion levels also appear linked to patient longevity should change how we think about the way forward for developing treatments for the disease. We need a sea change in Alzheimer’s disease research, and that is what this paper does. This paper might catalyze a major change in AD research.”
J Neurochem. 2016 Aug;138 Suppl 1(Suppl Suppl 1):163-83. doi: 10.1111/jnc.13668.
Prion-like propagation as a pathogenic principle in frontotemporal dementia
Prion-like propagation as a pathogenic principle in frontotemporal dementia
Acta Neuropathol. 2021; 142(2): 227–241.
Published online 2021 Jun 14. doi: 10.1007/s00401-021-02336-w
PMCID: PMC8270882
NIHMSID: NIHMS1721892
PMID: 34128081
Structure of Tau filaments in Prion protein amyloidoses
Grace I. Hallinan,#1 Md Rejaul Hoq,#2 Manali Ghosh,2 Frank S. Vago,2 Anllely Fernandez,1 Holly J. Garringer,1 Ruben Vidal,corresponding author1,3 Wen Jiang,corresponding author2 and Bernardino Ghetticorresponding author1
Abstract
In human neurodegenerative diseases associated with the intracellular aggregation of Tau protein, the ordered cores of Tau filaments adopt distinct folds. Here, we analyze Tau filaments isolated from the brain of individuals affected by Prion-Protein cerebral amyloid angiopathy (PrP-CAA) with a nonsense mutation in the PRNP gene that leads to early termination of translation of PrP (Q160Ter or Q160X), and Gerstmann–Sträussler–Scheinker (GSS) disease, with a missense mutation in the PRNP gene that leads to an amino acid substitution at residue 198 (F198S) of PrP. The clinical and neuropathologic phenotypes associated with these two mutations in PRNP are different; however, the neuropathologic analyses of these two genetic variants have consistently shown the presence of numerous neurofibrillary tangles (NFTs) made of filamentous Tau aggregates in neurons. We report that Tau filaments in PrP-CAA (Q160X) and GSS (F198S) are composed of 3-repeat and 4-repeat Tau isoforms, having a striking similarity to NFTs in Alzheimer disease (AD). In PrP-CAA (Q160X), Tau filaments are made of both paired helical filaments (PHFs) and straight filaments (SFs), while in GSS (F198S), only PHFs were found. Mass spectrometry analyses of Tau filaments extracted from PrP-CAA (Q160X) and GSS (F198S) brains show the presence of post-translational modifications that are comparable to those seen in Tau aggregates from AD. Cryo-EM analysis reveals that the atomic models of the Tau filaments obtained from PrP-CAA (Q160X) and GSS (F198S) are identical to those of the Tau filaments from AD, and are therefore distinct from those of Pick disease, chronic traumatic encephalopathy, and corticobasal degeneration. Our data support the hypothesis that in the presence of extracellular amyloid deposits and regardless of the primary amino acid sequence of the amyloid protein, similar molecular mechanisms are at play in the formation of identical Tau filaments.
snip...
Amyloid and Tau aggregates coexist in AD and in other diseases in addition to the group of the PrP Amyloidoses [22], two of which are reported here. In fact, in other hereditary cerebral amyloid diseases such as Familial British dementia (FBD) [34, 59] and Familial Danish dementia (FDD) [35, 60], a severe neurofibrillary Tau pathology occurs. Our study shows for the first time that Tau fibrils deposited in the brain of individuals with a brain amyloidosis other than AD are biochemically, antigenically, and structurally identical. Moreover, a recent study shows that Tau fibrils isolated from the brain of individuals with FBD and FDD are also structurally identical to those in AD [56]. The co-existence of Tau aggregates with different types of amyloids suggests a common mechanism through which amyloids, whether Aβ in AD, APrP in Prion diseases, ABri in FBD or ADan in FDD, trigger aggregation of Tau, resulting in Tau filaments with identical structure at their core (Fig. 5). Furthermore, Tau from the brains of patients with AD, GSS (F198S), and PrP-CAA (Q160X) have similar seeding activities in vitro, as has been also seen for brain homogenates from AD and PART [38]. For AD, it has been proposed that Aβ provides a crucial element toward Tau aggregation [4, 30]. This hypothesis has been supported by genetic forms of AD due to mutations in the AβPP, PSEN1, and PSEN2 genes that consistently alter the metabolism of Aβ, with a consequent Tau hyperphosphorylation and formation of Tau aggregates in vitro and in vivo [15, 19, 28]. Altered Tau metabolism in association with APrP has also been observed in in vitro studies [42] and in vivo in mouse models [48, 50]. By determining the structure of the core of Tau filaments from diseases caused by two distinct PRNP mutations, F198S and Q160X, to be identical to the core of Tau filaments from AD, we uncover potential links between amyloid proteins and the resulting Tau aggregation. Structural data are urgently needed for the identification of specific ligands for in vivo imaging of Tau aggregates in a wide range of neurodegenerative diseases.
Prog Mol Biol Transl Sci . 2020;175:239-259. doi: 10.1016/bs.pmbts.2020.08.003. Epub 2020 Sep 8.
Tau proteinopathies and the prion concept
Michel Goedert 1 Affiliations expand
PMID: 32958235 DOI: 10.1016/bs.pmbts.2020.08.003
Abstract
The ordered assembly of a small number of proteins into amyloid filaments is central to age-related neurodegenerative diseases. Tau is the most commonly affected of these proteins. In sporadic diseases, assemblies of tau form in a stochastic manner in certain brain regions, from where they appear to spread in a deterministic way, giving rise to disease symptoms. Over the past decade, multiple lines of evidence have shown that assembled tau behaves like a prion. More recently, electron cryo-microscopy of tau filaments has shown that distinct conformers are present in different diseases, with no inter-individual variation for a given disease.
Keywords: Alzheimer's disease; Chronic traumatic encephalopathy; Corticobasal degeneration; Electron cryo-microscopy; Pick's disease; Prion-like; Tau proteinopathy.
Tau prions from Alzheimer’s disease and chronic traumatic encephalopathy patients propagate in cultured cells
Amanda L. Woerman, Atsushi Aoyagi, Smita Patel, +6, and Stanley B. Prusiner stanley.prusiner@ucsf.eduAuthors Info & Affiliations Contributed by Stanley B. Prusiner, October 6, 2016 (sent for review August 5, 2016; reviewed by Robert H. Brown Jr. and David Westaway)
November 28, 2016
113 (50) E8187-E8196
Significance
The progressive nature of neurodegenerative diseases is due to the spread of prions, misfolded infectious proteins, in the brain. In tauopathies, the protein tau misfolds, causing several diseases, including Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE). Here we created a panel of mammalian cell lines expressing a fragment of tau fused to yellow fluorescent protein. Each cell line selectively detects tau prions that are misfolded into self-propagating conformations; such cells permit identification of minute differences among tauopathies. For example, tau prions in AD and CTE are distinct from prions in other tauopathies such as Pick’s disease and progressive supranuclear palsy. These insights are likely to contribute to the development of future therapeutics.
Aβ and tau prions feature in the neuropathogenesis of Down syndrome
Carlo Condello carlo.condello@ucsf.edu, Alison M. Maxwell, Erika Castillo https://orcid.org/0000-0003-2492-901X, +9, and Stanley B. Prusiner
https://orcid.org/0000-0003-1955-5498 stanley.prusiner@ucsf.eduAuthors Info & Affiliations
Contributed by Stanley Prusiner; received August 1, 2022; accepted September 27, 2022; reviewed by Robert Brown Jr. and Neil Cashman.
November 7, 2022
119 (46) e2212954119
Significance
Approximately 5.4 million people worldwide have Down syndrome (DS), which is caused by trisomy of chromosome 21 (Chr21). The APP gene is one of approximately 250 protein-coding genes located on Chr21, and its duplication is associated with elevated Aβ production and increased incidence of Alzheimer’s disease (AD) neuropathology in most aged individuals with DS. Since AD brains have plaques composed of Aβ prions and neurofibrillary tangles composed of tau prions, we asked if DS brains have both Aβ and tau prions. We found that the age-dependent kinetics of Aβ and tau prions are distinct in DS and could even be detected in a 19-y-old individual. Whether DS is an ideal model for assessing efficacy of putative AD therapeutics remains unknown.
Abstract
Down syndrome (DS) is caused by the triplication of chromosome 21 and is the most common chromosomal disorder in humans. Those individuals with DS who live beyond age 40 y develop a progressive dementia that is similar to Alzheimer’s disease (AD). Both DS and AD brains exhibit numerous extracellular amyloid plaques composed of Aβ and intracellular neurofibrillary tangles composed of tau. Since AD is a double-prion disorder, we asked if both Aβ and tau prions feature in DS. Frozen brains from people with DS, familial AD (fAD), sporadic AD (sAD), and age-matched controls were procured from brain biorepositories. We selectively precipitated Aβ and tau prions from DS brain homogenates and measured the number of prions using cellular bioassays. In brain extracts from 28 deceased donors with DS, ranging in age from 19 to 65 y, we found nearly all DS brains had readily measurable levels of Aβ and tau prions. In a cross-sectional analysis of DS donor age at death, we found that the levels of Aβ and tau prions increased with age. In contrast to DS brains, the levels of Aβ and tau prions in the brains of 37 fAD and sAD donors decreased as a function of age at death. Whether DS is an ideal model for assessing the efficacy of putative AD therapeutics remains to be determined.
